Looking for students or interns
Areas of expertise
Antiviral innate immunity , Emerging Viruses , Host–Pathogen Interactions , Interferon Response , Molecular virology
- Professor
Phone
450-687-5010 poste 4363
E-mail
sebastien.nisole@inrs.ca
Armand-Frappier Santé Biotechnologie Research Centre
531 des Prairies Blvd.
Laval, Quebec H7V 1B7
Research interests
Our team investigates how viruses interact with host cells by studying innate antiviral immunity. We focus on the interferon response and interferon-stimulated genes (ISGs), central players in controlling viral infections. Our research targets RNA viruses of significant public health concern, including HIV-1, influenza virus, SARS-CoV-2, and emerging mosquito-borne flaviviruses such as dengue (DENV), West Nile (WNV), and Zika (ZIKV) viruses. By integrating molecular virology, cell biology, and functional genomics, we aim to uncover how these viruses evade host defenses and to pave the way for innovative antiviral strategies.
Training openings for students or interns
Sébastien Nisole completed his PhD in Virology at the Pasteur Institute in Paris, France, where he studied the mechanisms of HIV-1 entry into target cells. After obtaining his doctorate in 2001, he received an EMBO fellowship to pursue postdoctoral research in the laboratory of Jonathan Stoye at the National Institute for Medical Research in London, UK. There, he investigated the mechanism by which the restriction factor TRIM5α inhibits retroviral replication.
In 2005, he was appointed lecturer at Paris Diderot University and subsequently became a full-time researcher at the French National Institute of Health and Medical Research (INSERM). He worked in several Parisian institutes, including the Institut Cochin, the Pasteur Institute, and the Faculty of Medicine of Saints-Pères. His research focused on the interferon response and on cellular factors that interfere with viral replication, with particular attention to the role of TRIM family proteins in intrinsic and innate antiviral responses.
From 2017 to 2025, he led the “Viral Trafficking, Restriction and Innate Signaling” (VTRIS) team at the Infectiology Research Institute in Montpellier, France, studying host-virus interactions and antiviral mechanisms towards pathogenic RNA viruses, including HIV-1, Influenza A virus, SARS-CoV-2, and arboviruses. He was promoted to Research Director at INSERM in 2024.
In 2025, he joined the INRS – Armand-Frappier Santé Biotechnologie Research Centre in Laval, Canada, as a full Professor, where his group studies how the interferon response controls RNA virus replication and how viruses evade these defenses, with a focus on emerging arboviruses.
Publications
– Bribes I, Zoladek J, Cannac M, Salinas S, Wilson SJ, Nisole S*. African strains of Zika virus resist ISG-mediated restriction. PLoS Negl Trop Dis. 2025, 19(7):e0013326.
– Medkour H, Pruvost L, Miot EF, Gong X, Vaissayre V, Tavadia M, Boutinaud P, Revel J, Hitakarun A, Sornjai W, Zoladek J, Duncan Smith R, Nisole S, Nolte-‘t Hoen E, Bertrand-Michel J, Missé D, Marti G, Pompon J. Sphingomyelins in mosquito saliva reconfigure skin lipidome to promote viral protein levels and enhance transmission of flaviviruses. Cell Metab. 2025, 37(7):1601-1614.
– Zoladek J, Cannac M, Seite M, Davies E, Quellec J, Barthelemy J, Gorna K, Desgraupes S, Bribes I, Salinas S, Coulpier M, Arhel NJ, Palmarini M, Simonin Y, Wilson SJ, Nisole S*. MITD1 is a brain-specific interferon-inducible factor that inhibits flavivirus replication. Proc Natl Acad Sci U S A. 2025, 122(12):e2502064122.
– Zoladek J, Deymier S, Cimarelli A, Nisole S*. Not all RNAs are created equal for the antiviral RNase ISG20. Trends Microbiol. 2025, 33(6):583-585.
– Zoladek J, Caval V, Paillart JC, Decroly E, Nisole S*. How Usutu virus resists ISG20-mediated restriction. Med Sci. 2024, 40(12):973-975.
– Bekaddour N, Smith N, Caspar B, Grinberg S, Giorgiutti S, Rodeschini V, Dupuy S, Leboulanger N, Duffy D, Soulas-Sprauel P, Gies V, Korganow AS, Nisole S, Herbeuval JP. The histamine analogue clobenpropit modulates IRF7 phosphorylation and interferon production by targeting CXCR4 in systemic lupus erythematosus models. Front. Immunol. 2024, 15:1490593.
– Zoladek J, El Kazzi P, Caval V, Vivet-Boudou V, Cannac M, Davies EL, Rossi S, Bribes I, Rouilly L, Simonin Y, Jouvenet N, Decroly E, Paillart JC, Wilson SJ, Nisole S*. A specific domain within the 3′ untranslated region of Usutu virus confers resistance to the exonuclease ISG20. Nat Commun. 2024, 15(1):8528.
– Quellec J, Piro-Megy C, Cannac M, Nisole S, Marty FH, Gosselet F, Shimizu F, Kanda T, Cêtre-Sossah C, Salinas S. Rift Valley fever virus is able to cross the human blood-brain barrier in vitro by direct infection with no deleterious effects. J Virol. 2024.
– Nisole S*. 2024: The Olympic Games go viral. Virologie. 2024, 28(5):301-303.
– Cannac M, Nisole S*. TRIMming down Flavivirus Infections. Viruses. 2024, 16(8):1262.
– Decombe A, El Kazzi P, Nisole S, Decroly E. How do 2′-O-methylations within Human Immunodeficiency Virus type 1 (HIV-1) genome regulate its replication? Med Sci. 2024, 40(5):421-427.
– Vouillon A, Barthelemy J, Lebeau L, Nisole S, Savini G, Lévêque N, Simonin Y, Garcia M, Bodet C. Skin tropism during Usutu virus and West Nile virus infection: an amplifying and immunological role. J Virol. 2023 Dec 13:e0183023.
– Decombe A, Peersen O, Sutto-Ortiz P, Chamontin C, Piorkowski G, Canard B, Nisole S, Decroly E. Internal RNA 2′-O-methylation on the HIV-1 genome impairs reverse transcription. Nucleic Acids Res. 2024, 52(3):1359-1373.
– Gouy B, Decorsière A, Desgraupes S, Duan W, Ouyang H, Wang YE, Yeh EA, Palazzo AF, Moraes TJ, Nisole S, Arhel NJ. Rapid and inexpensive bedside diagnosis of RAN binding protein 2-associated acute necrotizing encephalopathy. Front. Neurol. 2023, 14:1282059.
– Zoladek J and Nisole S*. Mosquito-borne flaviviruses and type I interferon: catch me if you can! Front. Microbiol. 2023, 14:1257024.
– Nisole S*, Gilmer D*. Renaud-Mahieux prizes – XXVth JFV. Virologie. 2023, 27(3):203.
– Bekaddour N, Smith N, Beitz B, Llibre A, Dott T, Baudry A, Korganow AS, Nisole S, Mouy R, Breton S, Bader-meunier B, Duffy D, Terrier B, Schneider B, Quartier P, Rodero MP, Herbeuval JP. Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis. Front. Immunol. 2023, 14:1178172.
– Zoladek J, Cannac M, Cartron M, Léocadie T, Wilson SJ, Nisole S*. Identification of interferon-stimulated genes that interfere with the replication of West Nile virus and Usutu virus. Virologie. 2023, 27(3):204-205.
– Boulay A, Trabanelli S, Boireau S, Boyer-Clavel M, Nisole S, Romero P, Jandus C, Beignon AS, Arhel NJ. Assessing the Impact of Persistent HIV Infection on Innate Lymphoid Cells Using In Vitro Models. Immunohorizons. 2023 Mar 1;7(3):243-255.
– El Kazzi P, Rabah N, Chamontin C, Poulain L, Ferron F, Debart F, Canard B, Missé D, Coutard B, Nisole S, Decroly E. Internal RNA 2’O-methylation in the HIV-1 genome counteracts ISG20 nuclease-mediated antiviral effect. Nucleic Acids Research, 2023, 51(6):2501-2515.
– Vitour D*, Nisole S*, Lévêque N*, Saulnier A*, Tordo N*, Gatignol A*, Gilmer D*. A year in Virologie: some viruses persist, others emerge. Virologie. 2022, 26(6):405-408.
– Constant O, Maarifi G, Barthelemy J, Martin MF, Tinto B, Savini G, Van de Perre P, Nisole S, Simonin Y, Salinas S. Differential effects of Usutu and West Nile viruses on neuroinflammation, immune cell recruitment and blood brain barrier integrity. Emerg Microbes Infect. 2022, 12(1):2156815.
– Pompon J, Nisole S*. How flaviviruses make our skin tastier for mosquitoes. Virologie. 2022, 26(4):315-317.
– Maarifi G, Martin MF, Zebboudj A, Boulay A, Nouaux P, Fernandez J, Lagisquet J, Garcin D, Gaudin R, Arhel NJ, Nisole S*. Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. Cell Chem Biol. 2022, 29(7):1113-1125.
– Mac Kain A, Maarifi G, Aicher SM, Arhel NJ, Baidaliuk A, Munier S, Donati F, Vallet T, Tran QD, Hardy A, Chazal M, Porrot F, OhAinle M, Carlson-Stevermer J, Oki J, Holden K, Zimmer G, Simon-Lorière E, Bruel T, Schwartz O, van der Werf S, Jouvenet N*, Nisole S*, Vignuzzi M*, Roesch F*. Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen. Nat Commun. 2022, 13(1):2442.
– Martin MF, Maarifi G, Abiven H, Seffals M, Mouchet N, Beck C, Bodet C, Lévèque N, Arhel NJ, Blanchet FP, Simonin Y, Nisole S*. Usutu Virus escapes langerin-induced restriction to productively infect human Langerhans cells, unlike West Nile virus. Emerg Microbes Infect. 2022, 11(1):761-774.
– Chamontin C, Bossis G, Nisole S, Arhel NJ, Maarifi G. Regulation of viral restriction by post-translational modifications. Viruses. 2021, 13: 2197.
– Maarifi G, Lagisquet J, Hertel Q, Bonaventure B, Chamontin C, Fuchs K, Moncorgé O, Tauziet M, Mombled M, Papin L, Molès JP, Bodet C, Lévèque N, Gross A, Arhel N, Nisole S, Van de Perre P, Goujon C, Blanchet FP. Alarmin S100A9 restricts retroviral infection by limiting reverse transcription in human dendritic cells. EMBO J. 2021, 40(16):e106540.
– Gosselin-Grenet AS, Servan de Almeida R, Roumagnac P, Ayouba A, Simonin Y, Nisole S*. Viruses and scientists under the sun of Montpellier. Virologie. 2021, 25(S1):3-5.
– Rebendenne A, Valadão ALC, Tauziet M, Maarifi G, Bonaventure B, McKellar J, Planès R, Nisole S, Arnaud-Arnould M, Moncorgé O, Goujon C. SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. J Virol. 2021, JVI.02415-20.
– Fernandez J, Hassen-Khodja C, Georget V, Rose T, Jacob Y, Janin YL, Nisole S, Vidalain PO, Arhel NJ. Measuring the subcellular compartmentalization of viral infections by protein complementation assay. Proc Natl Acad Sci U S A. 2021, 118(2):e2010524118.
– Clé M, Desmetz C, Barthelemy J, Martin MF, Constant O, Maarifi G, Foulongne V, Bolloré K, Glasson Y, De Bock F, Blaquiere M, Dehouck L, Pirot N, Tuaillon E, Nisole S, Najioullah F, Van de Perre P, Cabié A, Marchi N, Gosselet F, Simonin Y, Salinas S. Zika Virus Infection Promotes Local Inflammation, Cell Adhesion Molecule Upregulation, and Leukocyte Recruitment at the Blood-Brain Barrier. mBio. 2020, 11(4):e01183-20.
– Sa Ribero M, Jouvenet N, Dreux M, Nisole S*. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020, 16(7):e1008737.
– Nisole S, Saulnier A, Gatignol A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease? Virologie. 2020, 24(3):135-141.
– Maillet S, Fernandez J, Decourcelle M, El Koulali K, Blanchet FP, Arhel NJ, Maarifi G, Nisole S*. Daxx inhibits HIV-1 reverse transcription and uncoating in a SUMO-dependent manner. Viruses. 2020, 12(6):E636.
– Burette M, Allombert J, Lambou K, Maarifi G, Nisole S, Di Russo Case E, Blanchet FP, Hassen-Khodja C, Cabantous S, Samuel J, Martinez E, Bonazzi M. Modulation of innate immune signaling by a Coxiella burnetii eukaryotic-like effector protein. Proc Natl Acad Sci U S A. 2020, 117(24):13708-13718.
– Martin MF, Nisole S*. West Nile Virus restriction in mosquito and human cells: A virus under confinement. Vaccines. 2020, 8(2):E256.
– Maarifi G, Nisole S*. Interferon response: with great power comes great responsibility. Med Sci. 2020, 36(3):206-209.
– Maarifi G, Czubala MA, Lagisquet J, Ivory MO, Fuchs K, Papin L, Birchall JC, Nisole S, Piguet V, Blanchet FP. Langerin (CD207) represents a novel interferon-stimulated gene in Langerhans cells. Cell Mol Immunol. 2020,17(5):547-549.
– Hayek S, Pietrancosta N, Hovhannisyan AA, Alves de Sousa R, Bekaddour N, Ermellino L, Tramontano E, Arnould S, Sardet C, Dairou J, Diaz O, Lotteau V, Nisole S, Melikyan G, Herbeuval JP, Vidalain PO. Cerpegin-derived furo[3,4-c]pyridine-3,4(1H,5H)-diones enhance cellular response to interferons by de novo pyrimidine biosynthesis inhibition. Eur J Med Chem. 2020, 186:111855.
– Salinas S, Simonin Y, L’Ambert G, Nisole S*. Autochthonous cases of Zika virus in metropolitan France: a new paradigm for this arbovirus? Virologie. 2019, 23(6):329-332.
– Maarifi G, Smith N, Maillet S, Moncorgé O, Chamontin C, Edouard J, Sohm F, Blanchet FP, Herbeuval JP, Lutfalla G, Levraud JP, Arhel NJ, Nisole S*. TRIM8 is required for virus-induced IFN response in human plasmacytoid dendritic cells. Science Adv. 2019, 5(11):eaax3511.
– Fernandez J, Machado AK, Lyonnais S, Chamontin C, Gärtner K, Léger T, Henriquet C, Garcia C, Portilho DM, Pugnière M, Chaloin L, Muriaux D, Yamauchi Y, Blaise M, Nisole S, Arhel NJ. Transportin-1 binds to the HIV-1 capsid via a nuclear localization signal and triggers uncoating. Nat Microbiol. 2019, 4(11):1840-1850.
– Smith N, Rodero MP, Bekaddour N, Bondet V, Ruiz-Blanco YB, Harms M, Mayer B, Badder-Meunier B, Quartier P, Bodemer C, Baudouin V, Dieudonné Y, Kirchhoff F, Garcia ES, Charbit B, Leboulanger N, Jahrsdörfer B, Richard Y, Korganow AS, Münch J, Nisole S, Duffy D and Herbeuval JP. Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment. Science Adv. 2019, 5(7):eaav9019.
– Hayek S, Bekaddour N, Besson L, Alves de Sousa R, Pietrancosta N, Viel S, Smith N, Jacob Y, Nisole S, Mandal R, Wishart DS, Walzer T, Herbeuval JP, Vidalain PO. Identification of primary natural killer cell modulators by chemical library screening with a luciferase based functional assay. SLAS Discovery. 2019, 24(1):25-37.
– Nisole S*, Fernandez J, Maarifi G, Arhel NJ*. SUMO regulates the capacity of TRIM5α to inhibit HIV-1. Med Sci. 2019, 35(2):106-109.
– Maarifi G, Fernandez J, Portilho DM, Boulay A, Dutrieux, J, Oddos S, Butler-Browne G, Nisole S, Arhel NJ. RanBP2 regulates the anti-retroviral activity of TRIM5α by SUMOylation at a predicted phosphorylated SUMOylation motif. Commun Biol. 2018, 1:193.
– Nisole S*. Usutu, that which does not kill us, makes us stronger. Virologie. 2018, 22(5):231-2.
– Lucas-Hourani M, Dauzonne D, Mulier-Lehmann H, Khiar S, Nisole S, Dairou J, Helynck O, Afonso P, Tangy F, Vidalain PO. An original chemical series of pyrimidine biosynthesis inhibitors that boost the antiviral interferon response. Antimicrob. Agents Chemother. 2017, 61(10): e00383-17.
– Khiar S, Lucas-Hourani M, Nisole S, Smith N, Helynck O, Bourgine M, Ruffié C, Herbeuval JP, Munier-Lehmann H, Tangy F, Vidalain PO. Identification of a small molecule that primes the type I interferon response to cytosolic DNA. Sci Rep. 2017, 7(1):2561.
– Smith N, Pietrancosta N, Davidson S, Dutrieux J, Chauveau L, Cutolo P, Dy M, Scott-Algara D, Manoury B, Zirafi O, McCort-Tranchepain I, Durroux T, Bachelerie F, Schwartz O, Münch J, Wack A, Nisole S, Herbeuval JP. Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement. Nat Commun. 2017, 8:14253.
– Maarifi G, Hannoun Z, Geoffroy MC, El Asmi F, Zarrouk K, Nisole S, Blondel D, Chelbi-Alix M. MxA mediates SUMO-induced resistance to Vesicular Stomatitis Virus. J Virol. 2016, 90(14):6598-610.
– Smith N, Vidalain PO, Nisole S, Herbeuval JP. An efficient method for gene silencing in human primary plasmacytoid dendritic cells: silencing of the TLR7/IRF 7 pathway as a proof of concept. Sci Rep. 2016, 6:29891.
– Portilho DM, Fernandez J, Ringeard M, Machado AK, Boulay A, Mayer M, Müller-Trutwin M, Beignon AS, Kirchhoff F, Nisole S, Arhel NJ. Endogenous TRIM5α function is regulated by SUMOylation and nuclear sequestration for efficient innate sensing in dendritic cells. Cell Reports. 2016, 14(2):355-69.
– Maillet S, Nisole S*. Daxx, a broad-spectrum viral restriction factor. Virologie, 2016, 20(5):261-72.
– Maarifi G, Dianoux L, Nisole S, Chelbi-Alix MK. SUMO paralogs and interferon response. Med Sci. 2016, 32(2):141-3.
– Dutrieux J, Maarifi G, Portilho DM, Arhel NJ, Chelbi-Alix MK, Nisole S*. PML/TRIM19-dependent inhibition of retroviral reverse-transcription by Daxx. PLoS Pathog. 2015, 11(11):e1005280.
– Maarifi G, Maroui MA, Dutrieux J, Dianoux L, Nisole S, Chelbi-Alix MK. SUMO promotes resistance to interferon. J Immunol. 2015, 195(5):2312-24.
– Dutrieux J, Portilho DM, Arhel NJ, Hazan U, Nisole S*. TRIM5α is a SUMO substrate. Retrovirology. 2015, 12:28.
– Brantis-de-Carvalho CE, Maarifi G, Gonçalves Boldrin PE, Zanelli CF, Nisole S, Chelbi-Alix MK, Valentini SR. MxA interacts with and is modified by the SUMOylation machinery. Exp Cell Res. 2015, 330(1):151-63.
– Blondel D, Maarifi G, Nisole S, Chelbi-Alix M. Resistance to Rhabdoviridae Infection and Subversion of Antiviral Responses. Viruses. 2015, 7:3675-702.
– Zebboudj A, Maroui MA, Dutrieux J, Boukoffa C, Bourouba M, Chelbi-Alix MK, Nisole S*. Sodium arsenite induces apoptosis and Epstein-Barr virus reactivation in lymphoblastoid cells. Biochimie. 2014, 107: 247-56.
– El Asmi F, Maroui MA, Dutrieux J, Blondel D, Nisole S, Chelbi-Alix MK. Implication of PMLIV in both intrinsic and innate immunity. PLoS Pathog. 2014, 10(2):e1003975.
– Maarifi G, Chelbi-Alix MK, Nisole S*. PML control of cytokine signaling. Cytokine Growth Factor Rev. 2014, 25(5):551-61.
– Maroui MA, El Asmi F, Dutrieux J, Chelbi-Alix M, Nisole S*. Implication of PML nuclear bodies in intrinsic and innate immunity. Med Sci. 2014, 30(8-9): 765-71.
– Nisole S, Maroui MA, Mascle XH, Aubry M, Chelbi-Alix. Differential roles of PML isoforms. Frontiers in Oncology, 2013, 3:125.
– Roesch F, Meziane O, Kula A, Nisole S, Porrot F, Anderson I, Mammano F, Fassati A, Marcello A, Benkirane M, Schwartz O. Hyperthermia stimulates HIV-1 replication. PLoS Pathogens. 2012, 8(7):e1002792.
– Di Nunzio F, Félix T, Arhel NJ, Nisole S, Charneau P, Beignon AS. HIV-derived vectors for therapy and vaccination against HIV. Vaccine, 2012, 30:2499-509.
– Maudet C, Bertrand M, Le Rouzic E, Lahouassa H, Ayinde D, Nisole S, Goujon C, Cimarelli A, Margottin-Goguet F, Transy C. Molecular insight into how HIV-1 Vpr protein impairs cell growth through two genetically distinct pathways. J Biol Chem. 2011, 286(27):23742-52.
– Bergamaschi A, David A, Le Rouzic E, Nisole S, Barré-Sinoussi F, Pancino G. The CDK inhibitor p21Cip1/WAF1 is induced by FcγR activation and restricts HIV-1 replication in human macrophages. J Virol. 2009, 83(23):12253-65.
– Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin-Goguet F, Mothes W, Hazan U, Transy C, Pancino G, Nisole S*. Human TRIM protein expression in response to interferons. PLoS ONE. 2009, 4(3):e4894.
– Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, DamondA F, Brun-Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C. The HIV-2 Vpx protein usurps the CUL4A-DDB1-DCAF1 ubiquitin ligase to overcome an early-acting restriction factor in macrophage infection. J Virol. 2009, 83(10):4854-60.
– Arhel NJ, Nisole S, Carthagena L, Coutant F, Souque P, Brussel A, Estaquier J, Charneau P. Lack of Endogenous TRIM5alpha-mediated restriction in rhesus macaque antigen presenting cells. Blood. 2008, 112(9):3772-6.
– Carthagena L, Parise MC, Ringeard M, Chelbi-Alix MK, Hazan U, Nisole S*. Implication of TRIM5α and TRIMCyp in interferon-induced anti-retroviral restriction activities. Retrovirology. 2008, 5(1):59.
– Delcroix-Genête D, Quan PL, Roger MG, Hazan U, Nisole S, Rousseau C. Antiviral properties of two soluble trimeric recombinant gp41 proteins. Retrovirology. 2006, 3(1):16.
– Cisse A, Darbandi-Tehrani K, Derache A, El Houry S, Marlin R, Pernet O, Nisole S*. Retroviral restriction factors : from Fv1 to TRIM5α. Virologie. 2006, 10:119-27.
– Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol. 2005, 15(1):73-8.
– Nisole S*, Stoye JP, Saïb A. TRIM family: Retroviral restriction and antiviral defence. Nature Reviews Microbiology. 2005, 3:799-808.
– Nisole S, Lynch C, Stoye JP, Yap MW. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci U S A. 2004, 101(36):13324-8.
– Yap MW, Nisole S, Lynch C, Stoye JP. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A. 2004, 101(29):10786-91.
– Nisole S, Saib A. Early steps of retrovirus replicative cycle. Retrovirology. 2004, 1(1):9.
– Said EA, Krust B, Nisole S, Svab J, Briand JP, Hovanessian AG. The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor. J Biol Chem. 2002, 277(40):37492-502.
– Nisole S, Krust B, Hovanessian AG. Anchorage of HIV on permissive cells leads to coaggregation of viral particles with surface nucleolin at membrane raft microdomains. Exp Cell Res. 2002, 276(2):155-73.
– Nisole S, Said EA, Mische C, Prevost MC, Krust B, Bouvet P, Bianco A, Briand JP, Hovanessian AG. The anti-HIV pentameric pseudopeptide HB-19 binds the C-terminal end of nucleolin and prevents anchorage of virus particles in the plasma membrane of target cells. J Biol Chem. 2002, 277(23):20877-86.
– Nisole S, Callebaut C, Briand JP, Krust B, Hovanessian AG. Inhibition of HIV infection by the cytokine midkine. Virology. 2001, 281(2):248-64.
– Hovanessian AG, Puvion-Dutilleul F, Nisole S, Svab J, Perret E, Deng JS, Krust B. The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res. 2000, 261(2):312-28.
– Nisole S, Krust B, Dam E, Bianco A, Seddiki N, Loaec S, Callebaut C, Guichard G, Muller S, Briand JP, Hovanessian AG. The HB-19 pseudopeptide 5[Kpsi(CH2N)PR]-TASP inhibits attachment of T lymophocyte- and macrophage-tropic HIV to permissive cells. AIDS Res Hum Retroviruses. 2000, 16(3):237-49.
– Nisole S, Krust B, Callebaut C, Guichard G, Muller S, Briand JP, Hovanessian AG. The anti-HIV pseudopeptide HB-19 forms a complex with the cell-surface-expressed nucleolin independent of heparan sulfate proteoglycans. J Biol Chem. 1999, 274(39):27875-84.
– Seddiki N, Nisole S, Krust B, Callebaut C, Guichard G, Muller S, Briand JP, Hovanessian AG. The V3 loop-mimicking pseudopeptide 5[Kpsi(CH2N)PR]-TASP inhibits HIV infection in primary macrophage cultures. AIDS Res Hum Retroviruses. 1999, 15(4):381-90.
– Dumonceaux J, Nisole S, Chanel C, Quivet L, Amara A, Baleux F, Briand P, Hazan U. Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol. 1998, 72(1):512-9.